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Viability, Differentiation Capacity, and Detectability
of Super-Paramagnetic Iron Oxide-Labeled Muscle
Precursor Cells for Magnetic-Resonance Imaging
Fahd Azzabi, PhD,1 Markus Rottmar, PhD,1,2 Virginija Jovaisaite, MSc,1 Markus Rudin, PhD,3
Tullio Sulser, MD,1 Andreas Boss, MD, PhD,2 and Daniel Eberli, MD, PhD1
Cell therapies are a promising approach for the treatment of a variety of human conditions including stress urinary
incontinence, but their success greatly depends on the biodistribution, migration, survival, and differentiation of
the transplanted cells. Noninvasive in vivo cell tracking therefore presents an important aspect for translation of
such a procedure into the clinics. Upon labeling with superparamagnetic iron oxide (SPIO) nanoparticles, cells can
be tracked by magnetic resonance imaging (MRI), but possible adverse effect of the labeling have to be considered
when labeling stem cells with SPIOs. In this study, human muscle precursor cells (hMPC) were labeled with
increasing concentrations of SPIO nanoparticles (100–1600mg/mL) and cell viability and differentiation capacity
upon labeling was assessed in vitro. While a linear dependence between cell viability and nanoparticle concen-
tration could be observed, differentiation capacity was not affected by the presence of SPIOs. Using a nude mouse
model, a concentration (400mg/mL) could be defined that allows reliable detection of hMPCs by MRI but does not
influence myogenic in vivo differentiation to mature and functional muscle tissue. This suggests that such an
approach can be safely used in a clinical setting to track muscle regeneration in patients undergoing cell therapy
without negative effects on the functionality of the bioengineered muscle.
Introduction
Stress urinary incontinence (SUI)–the involuntaryloss of urine–is a medical problem affecting millions of
people worldwide.1 While this condition not only markedly
decreases the quality of life of patients, annual direct costs of
caring amounts to $16 billion in the United States alone.2 SUI
occurs mainly due to a malfunction of the sphincter muscle,
which is located around the urethra and prevents urine from
leaking out of the bladder. If damaged, different strategies
including physical exercise, medications, interventional ther-
apies or surgery are currently used to treat the patient. How-
ever, such procedures alleviate the symptoms only temporarily
without providing permanent or at least long-term solutions.3–5
Stem cell therapies are a promising approach for the treat-
ment of human conditions where currently only limited or no
treatment options are available. Envisioned to replace damaged
or diseased cells, tissues, or organs in patients, a range of stem
cell therapy concepts that target different pathologies including
conditions of the heart, muscular dystrophy, diabetes, or Par-
kinson’s disease are currently being developed.6–11
Recent research shows that similar strategies using stem
cells have the potential to restore normal sphincter function
in patients affected by SUI.12,13 Stem cells can be either of
embryonic or adult origin and can be further divided in
muscular or nonmuscular cell types, which include but are
not limited to muscle precursor cells (MPCs), satellite cells
from muscle fibers, muscle-derived stem cells, mesenchy-
mal stem cells (MSCs), hematopoietic stem cells, and adi-
pose stem cells.12 MPCs are a promising source due to their
skeletal muscle origin and their restricted differentiation
potential toward muscle, which has been supported by ex-
cellent results in a large animal model showing a restoration
of 80% of initial sphincter pressure upon injection of MPCs
in dogs.14
The success of cell therapy approaches greatly depends
on the biodistribution, migration, survival, and differentia-
tion of the transplanted cells. Tracking of the hMPCs after
injection in vivo therefore presents an important aspect for
translation of such a procedure to the clinics. While traditional
histopathological techniques are too invasive to localize the
injected cells in a clinical setting, cellular imaging approaches
represent a noninvasive tool to follow implanted stem cells
and to evaluate the success of the therapeutic treatment.15,16
The most frequently employed techniques for cell track-
ing include magnetic resonance imaging (MRI), radioactive
labeling for positron emission tomography and single pho-
ton emission computed tomography, bioluminescence, and
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fluorescence. For clinical application, MRI is considered
a method of choice to track stem cells in vivo because of its
high spatial resolution on soft tissue structures, therefore
providing anatomical details of the graft area, which may also
help in detecting inflammation or edema.17,18 Moreover, MRI
is a well-established technology available in most clinical
centers.
While MRI offers excellent soft tissue contrast by design,
application of contrast enhancing gadolinium-chelates has
become an established tool in clinical practice. However,
the altered signal intensities between different tissues upon
application of intravenous contrast media mainly rely on
differences in uptake and washout of the agent, and the re-
laxivity of the applied gadolinium complex. Specificity of a
contrast agent is of paramount importance for identification
and tracking of specific entities such as cells and tissues but
the development of targeted, mostly peptide-based contrast
agents is still in its infancy.19 In the case of cell-based tissue
engineering concepts, nanoparticles that interfere with the
magnetic field can be used to label the cells prior to their use
in vivo. Such magnetic nanoparticles can be composed of
different elements including iron, manganese, or gadolinium
but the most popular ones are the superparamagnetic iron
oxide (SPIO) nanoparticles, which consist of an iron oxide
core with a polymeric or polysaccharide coating such as
dextran, carboxydextran, or polyethylene glycol to facilitate
stabilization and solubility of the particles.20 Provoking local
field inhomogeneities and subsequent spin-dephasing, SPIO
nanoparticles lead to a decreased signal on T2-weighted MR
images, thereby enabling the detection of the labeled cells as a
hypo-intense signal in the MR image.
Two SPIO formulations, ferumoxides (Feridex/Endorem)
and ferucarbotran (Resovist), are approved by the FDA for
clinical use in liver imaging,21 and have been used to label stem
cell types from different origin, including neural, endothe-
lial, mesenchymal, and hematopoietic tissues.22–26 Assessing
the possible negative effects of SPIO labeling on the stem cell
phenotype and cell behavior, reports significantly differ and
range from no effect to a minimal negative effect on cell via-
bility to inhibition of differentiation and migration.23–25,27–30 As
not only labeling efficiency, but also cell survival and behavior
appears cell and SPIO dependent, proliferation and differenti-
ation analysis should be considered when labeling stem cells
with SPIO.31–34
In this study, we demonstrate the labeling of hMPCs with
SPIO nanoparticles without additional transfection agents
and evaluate the possibility to track these cells over time in a
noninvasive manner. We present data defining the optimal
concentration for SPIO labeling without a negative effect on
viability, differentiation, and myofiber formation. Further-
more, we show that SPIO-labeled muscle tissue remains
traceable by T2-weighted MRI scans for 4 weeks and that
labeled hMPCs form muscle tissue in vivo with contractile
forces comparable to nonlabeled tissues, demonstrating that
such an approach would be suitable to monitor muscle re-
generation in a clinical setting.
Materials and Methods
Cell culture
hMPCs were derived from rectus abdominis muscle sam-
ples of consenting patients undergoing abdominal surgery at
the UniversityHospital Zurich. This procedure was approved
by the local ethics committee. The hMPCs were harvested
following established protocols.14,35 Briefly, muscle biop-
sies were minced and digested for 1 h at 37C 5% CO2 in
DMEM/F-12 (Gibco, Invitrogen) with 0.2% collagenase
type I (Worthington Biochemical) and 0.4% dispase (Gibco,
Grand Island). Samples were centrifuged, filtrated, and plated
on collagen-coated six-well dishes. To reduce the number of
fast adhering fibroblasts, the MPC-containing suspension was
replated after 24 h. Cells that attached to culture wells by day
4 after replating were used. hMPCs were cultured at 37C
in 5% CO2 with growth medium containing DMEM/F-12
(Gibco, Invitrogen) supplemented with 18% fetal bovine se-
rum (Gibco, Invitrogen), 1% penicillin/streptomycin (Gibco,
Invitrogen), 10mg/mL human epidermal growth factor (hEGF;
Sigma), 1mg/mL human basic fibroblast growth factor (hbFGF;
Sigma), 10 mg/mL human insulin (Sigma), and 0.4 mg/mL
dexamethasone (Sigma).
SPIO labeling
Cells were labeled with the clinically approved contrast
agent Endorem (Guerbet AG), consisting of dextran-coated
SPIO nanoparticles with a size distribution between 120 and
180 nm and an iron content of 11.2 mg/mL. hMPCs of the
second passage were cultivated in growth medium supple-
mented with 100, 200, 400, 800, or 1600 mg/mL SPIO na-
noparticles. After 24 h incubation the labeling medium was
removed and cells were analyzed.
Prussian blue staining
The efficiency of SPIO labeling was determined by Prus-
sian blue staining. Unlabeled (control) and labeled MPCs
were washed with phosphate-buffered saline (PBS), fixed
with 4% paraformaldehyde for 15 min, incubated for 30 min
with 2% potassium ferrocyanide (Sigma) in 2% hydrochloric
acid solution (Perl’s reagent), and counterstained with nuclear
fast red (Sigma).
Viability
Viability of SPIO-labeled MPCs was assessed by Trypan
Blue (Sigma) exclusion assay 24 h after iron oxide addition.
After trypsinizing, the blue positive (nonviable) and un-
stained (live) cells were counted separately; a minimum of
100 cells per condition per sample were counted in total.
Cell proliferation
Cell proliferation was evaluated by MTT assay for two
passages after labeling. Labeled MPCs were seeded in 24-
well plates at a density of 3000 cells/cm2. To generate a
growth curve, triplicates of each condition were analyzed by
MTT assay every 24 h for 7 days. Cells were incubated with
growth medium containing 0.5 mg/mL Thiazolyl blue (Sig-
ma) for 1 h at 37C. After removing the media, cells were
lysed with dimethyl sulfoxide (Sigma) for 15 min and the
intensity of the color was measured at 570 nm with a Synergy
HT Microplate reader (BioTek Instruments, Inc.).
Myogenic differentiation
To induce myogenic differentiation, MPCs were cultured
for 8 days in differentiation medium, containing DMEM/F-12
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(Gibco, Invitrogen) supplemented with 10% fetal bovine
serum (Gibco, Invitrogen) and 1% penicillin/streptomycin
(Gibco, Invitrogen). The hMPCs treated with SPIO for 24 h
were subjected to this regimen directly after the labeling and
in the following passage.
To evaluate the myofiber formation cells were fixed with
methanol for 7 min, air dried, and stained with Giemsa so-
lution (diluted 1:20 with deionized water; J.T. Baker) for
1 h. Number of nuclei per fiber and percent of fused cells
were counted in five pictures of 20 · magnification taken for
each SPIO labeling condition. A differentiation ratio was
calculated by dividing the nuclei in fibers by all nuclei.
Flow cytometry analysis
Labeled MPCs at P2 were split and cultivated until con-
fluence prior to flow cytometry analysis. Harvested MPCs
were fixed in 2% formaldehyde for 10 min and permeabi-
lized in 0.5% Triton X-100 for 7 min. Primary mouse anti-
bodies raised against human IgG (1:40; Santa Cruz), MyoD
(1:100; BD Pharmingen), myosin heavy chain (MyHC,
1:100; Santa Cruz), desmin (1:100; Sigma), a-actinin (1:200;
Sigma), and CD34 (1:100; BD Biosciences) and secondary
fluorescent goat anti-mouse IgG-FITC (1:200; BD Pharmin-
gen) were used for analysis. Cell fluorescence was measured
with a Becton-Dickinson FACS Canto Machine and data
were analyzed using FlowJo software.
Immunofluorescence
After labeling MPCs were fixed in 4% paraformaldehyde
for 10 min, permeabilized in 0.5% Triton X-100 for 7 min and
blocked with 1% bovine serum albumin (BSA) for 20 min.
Primary mouse antibodies raised against human MyoD (1:50;
BD Pharmingen), MyHC (1:100; Santa Cruz), desmin (1:100;
Sigma), a-actinin (1:500; Sigma), and secondary rabbit anti-
mouse antibody Cy3 IgG (1:1000; Sigma) together with
Phalloidin (1:100; Sigma) and DAPI (1:100; Sigma) were
used for staining.
Cell transplantation
A total of 44 nude female mice (CD-1.nu-Crl1, Crl:CD1-
Foxn1nn; Charles River Laboratories) were used as hMPC
recipients. The mice were split into two groups with 22 mice
each and each group received injections with either control
cells or SPIO-labeled cells. All procedures were performed
in accordance with the regulations of the cantonal veterinary
office Zurich.
hMPCs were labeled with 400 mg/mL SPIO for 24 h
before injection. Unlabeled hMPCs were used as a con-
trol. Cells were washed with PBS (Gibco, Invitrogen),
labeled using a PKH67 green fluorescent dye (Sigma),
and suspended in 1% collagen type I solution (BD Bio-
sciences). Subcutaneous injections of 1 · 107 hMPCs were
performed on the left and right sides of the back of nude
mice. During injection animals were anesthetized with
3% isoflurane.
Histology
After sacrificing the mice, the tissue-engineered muscles
were excised from the back, fixed in formalin for 48 h,
embedded in paraffin, and sectioned at 5 mm. For Prussian
blue staining, the sections were deparaffinized and stained in
Perl’s reagent (2% potassium ferrocyanide [Sigma] in 2%
hydrochloric acid solution) for 20 min at 60C. Slides were
counterstained with nuclear fast red (Sigma).
For immunostaining, the sections were deparaffinized,
permeabilized in 0.1% Proteinase K (Sigma) solution for
30 min at 37C, and blocked with 5% BSA 0.3% Triton X-
100 for 1 h. Primary mouse antibodies against human MyHC
(1:100; Santa Cruz), desmin (1:50; Sigma), and a-actinin
(1:500; Sigma) and secondary rabbit anti-mouse antibody
Cy3 IgG (1:1000; Sigma) together with DAPI (1:100; Sig-
ma) were used for muscle fiber staining.
Macrophage staining was performed on paraffinized
sections using primary rat antibody against mouse F4/80
(1:100; BMA Biomedicals) and secondary biotinylated
anti-rat IgG (1:200; Vector Laboratories) with ABC reagent.
Liquid DAB+Substrate Chromogen System (Dako) was used
to visualize the staining.
To visualize PKH67 staining, the tissue strips were frozen
and sectioned at 15 mm. Sections were fixed with 4% for-
malin and autofluorescence was reduced by incubation with
0.3 M glycine (Sigma) in PBS. Sections were counterstained
with DAPI (1:100; Sigma).
Organ bath
Two and 4 weeks after hMPC injection, the tissues were
harvested and their contractility evaluated. The muscle strips
were fastened with suture loops in Radnoti tissue bath cham-
bers. The tissues were immersed in Krebs solution (119 mM
NaCl, 4.4 mM KCl, 20 mM NaHCO3, 1.2 mM NaH2PO4,
1.2 mM MgCl2, 2.5 mM CaCl2, and 11 mM glucose) under
constant oxygenation at room temperature. Muscle strips were
stimulated with increasing electrical-field stimulation (40 Hz
at 40 V and 80 Hz at 80 V). Contractions were recorded and
their values were normalized to the sample weight (mg/mg
of tissue). Tension values recorded under 40 V/40 Hz and
80 V/80 Hz stimulation were used to compare the contractility
of unlabeled and SPIO-labeled tissue-engineered muscles 4
weeks after injection.
Magnetic resonance imaging
Phantoms were prepared using culture dishes filled with
1.6% agar (Sigma) in PBS. Drill holes (4 mm diameter)
were loaded with 35 mL of suspensions with 1.5 · 105 freshly
labeled cells in agar. After solidification the drill holes were
closed with additional agar.
Mice were subjected to MRI analysis 4 days, 1 week, 2
weeks, and 4 weeks after hMPC transplantation. During
the imaging process mice were anesthetized with 1.5%
isoflurane.
All measurements were performed in a Bruker 4.7 T
Pharmascan 47/16 (Bruker BioSpin MRI GmbH) with a
gradient strength of 375 mT/m and a slew rate of 3375 T/m/s
equipped with a circular polarized 1H mouse whole body
transmit-receive RF coil. After a gradient-echo localizer in
three spatial directions, the T2-weighted MR images were
acquired using Rapid Acquisition with Relaxation Enhance-
ment sequence (RARE; TE = 15 ms, TR 4500 ms, RARE
factor 8, number of averages = 5, slice thickness = 1 mm,
FoV 40 · 40 mm, Matrix 384 · 384, and acquisition time
17 min 38 s).
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Statistics
Experiments were repeated with hMPCs isolated from
at least three human donors. All assays and stainings were
performed in triplicate. Data were analyzed by Student’s
t-test or one-way ANOVA with Bonferroni post hoc
analysis. The results are presented as a mean value – SD
or – SEM depending on the test. Data with a value p < 0.05
were considered as significant.
Results
SPIO labeling of hMPCs
hMPCs labeled for 24 h with SPIOs at different concen-
trations ranging from 100 to 1600mg/mL were stained for iron
oxides with Prussian blue to assess the labeling efficiency.
Directly after labeling, hMPCs displayed an increasingly
strong blue staining when exposed to increasing concentra-
tions of SPIOs (Fig. 1a). Notably, nanoparticles concentrated
mostly in the perinuclear region of the cytoplasm. One pas-
sage after SPIO labeling, the cells still stained positive for
iron oxide, although in a more diluted manner (Fig. 1b). Im-
portantly, cell morphology did not change in response to
labeling with increasing concentrations of SPIOs. After la-
beling with SPIOs, hMPCs were also embedded in an agar gel
and examined by MRI (Fig. 2). The T2-weighted MR-images
showed a decreasing signal with higher concentrations of
SPIOs. This inverse monotone behavior could be observed for
both, cells imaged directly after labeling (Fig. 2a) and cells
imaged one passage after labeling (Fig. 2b), the latter show-
ing, however, a much weaker signal attenuation.
Cytocompatibility of SPIO labeling
Possible toxic effects of the SPIO labeling on hMPCs
were assessed by Trypan Blue exclusion assay 24 h after la-
beling. While cell viability was largely unaffected with na-
noparticle concentrations of 100 and 200 mg/mL (Fig. 3a), it
was significantly reduced for higher SPIO concentrations,
decreasing to 92%, 86%, and 77% for concentrations of 400,
800, and 1600 mg/mL, respectively, showing a linear depen-
dence between SPIO concentration and viability (r2 = 0.995).
However, cell growth was not affected by the presence of
SPIOs, as growth curves for the different conditions all fol-
lowed the same S-shaped curve, showing overlapping values
up to one passage after labeling (Fig. 3b, c).
Influence of SPIO labeling on the muscle phenotype
and differentiation capacity
To confirm the muscle phenotype of the hMPCs, FACS
analysis was performed assessing the expression of specific
skeletal muscle markers MyoD, MyHC, desmin, and a-actinin
(Fig. 4a). Notably, all investigated markers were expressed at
similar levels in both the control and the SPIO-labeled cells,
with differentiation markers MyHC, desmin, and a-actinin
being highly expressed with 95%, 90%, and 97%, respectively,
indicating populations of a partly differentiated phenotype.
Similarly, immunocytochemical stainings for MyoD, MyHC,
FIG. 1. Superparamagnetic iron
oxide (SPIO) uptake by hMPCs.
hMPCs were treated with SPIO
nanoparticles at concentrations of
0–1600 mg/mL and stained for iron
(a) directly after SPIO labeling and
(b) one passage (9 population
doublings) after SPIO labeling.
Scale bar is 50 mm. hMPCs, human
muscle precursor cells. Color ima-
ges available online at www
.liebertpub.com/tec
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desmin, and a-actinin showed equal expression levels in cells
with and without SPIO labeling (Fig. 4b). Furthermore, the
fiber formation assay (Supplementary Fig. S1; Supplementary
Data are available online at www.liebertpub.com/tec) was used
to evaluate the differentiation capacity of hMPCs, showing no
significant changes among the investigated concentrations
(Fig. 4c, d; 7.4– 1.4 nuclei per fiber formed; 22.7%– 4.3%
differentiation ratio).
Tracking of hMPCs in vivo
Evaluating the ability to track hMPCs in an in vivo envi-
ronment, either labeled (400 mg/mL) or nonlabeled hMPCs
were mixed with a collagen solution, injected subcutaneously
in the backsides of nude mice, and imaged by MRI (Fig. 5).
Over the period of 4 weeks, T2-weighted MRI images clearly
showed the position of the injected hMPCs as a protuberance
in the subcutaneous area. While the control cells displayed a
bright signal, the labeled cells appeared dark due to the signal
loss caused by the presence of SPIOs. Over time, the volume
of the injected hMPCs decreased, showing a reduction in
sample weight from day 14 to 28 of 16.7% (data not shown).
Evaluation of in vivo muscle formation
by histological analysis
To assess the myogenic in vivo differentiation of the in-
jected hMPCs, the newly formed tissue was evaluated by
histological analysis (Fig. 6). Macroscopically, the tissue-
engineered muscle was a distinct object in the subcutaneous
space of nude mice, remaining at the site of injection
throughout the experiment. H&E staining and immunohis-
tochemical stainings of both labeled and nonlabeled hMPCs
showed distinct myofibers that strongly expressed skeletal
muscle marker proteins desmin, MyHC, and a-actinin (Fig.
6a). The sections also showed longitudinally or transversely
cut muscle fibers with sarcomeric striations and centrally and
peripherally localized nuclei. PKH67 labeling of the hMPCs
furthermore demonstrated that the newly formed muscle tis-
sue was formed by human cells only (Supplementary Fig. S2).
Simultaneously, tissue sections were stained by Prussian
blue to facilitate iron detection (Fig. 6b). When staining
tissue-engineered fibers originating from nonlabeled cells,
no iron was detected. In tissue sections from mice injected
with 400mg/mL SPIO-labeled MPCs, large accumulation of
iron oxide could be detected over the course of 4 weeks.
Iron particles were present within the newly formed muscle
fibers after 4 weeks postinjection, but could also be observed
localized to single cells (Fig. 6c). In some regions of the
engineering muscle tissue, staining for mouse macrophages
using an F4/80 antibody revealed co-localization of the iron
oxide nanoparticles with macrophages (Fig. 6d).
Functionality of newly formed muscle tissue
Functionality of the tissue-engineered muscle was as-
sessed via myography. The tissues displayed distinct
muscle contractions after electrical stimulation of 40 V/
40 Hz and 80 V/80 Hz (Fig. 7). Contractile forces of muscle
formed by SPIO-labeled MPCs were comparable to the
ones originating from MPCs without SPIO labeling at 40 V/
40 Hz and displayed a statistically not significant difference
at 80 V/80 Hz.
Discussion
Monitoring the fate, distribution, and engraftment of the
stem cells in the host is a major concern in cell therapy con-
cepts. Therefore, reliable and noninvasive tracking of the
cells in vivo is of great interest before translation of such
approaches to clinical routine use. There are many imag-
ing techniques and labeling strategies available for noninva-
sive live cell tracking, each possessing unique advantages
but also distinct disadvantages.36 Among those approaches,
monitoring of SPIO-labeled cells in vivo by MRI has shown
FIG. 2. T2-weighted MR images of SPIO-labeled hMPCs
in an agar phantom. 1.5 · 105 hMPCs were treated with SPIO
nanoparticle concentrations of 0–1600 mg/mL, embedded in
an agar gel and imaged on a 4.7 T magnetic resonance im-
aging (MRI) system (a) directly after SPIO labeling and (b)
one passage (9 population doublings) after SPIO labeling.
FIG. 3. Assessment of cell viability and cell growth after SPIO labeling. hMPCs were treated with SPIO nanoparticles at
concentrations of 0–1600 mg/mL. (a) Viability of labeled hMPCs was assessed via Trypan Blue exclusion assay 24 h after
SPIO treatment (one-way ANOVA, *p < 0.05 ***p < 0.001 compared to control). Growth curves of labeled hMPCs were
obtained via MTT assay (b) 24 h after SPIO labeling and (c) one passage (9 population doublings) after SPIO labeling.
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FIG. 4. Analysis of muscle-specific protein expression and myogenic differentiation capacity of hMPCs after SPIO
labeling. hMPCs were treated with SPIO nanoparticles at concentrations of 0–1600 mg/mL and evaluated for expression of
muscle-specific proteins one passage (9 population doublings) after SPIO labeling via (a) FACS analysis and (b) im-
munostaining (only unlabeled and 400mg/mL SPIO labeled cells are shown). Differentiation capacity of labeled MPCs one
passage after SPIO labeling was evaluated in terms of (c) myotube size (nuclei per fiber) and (d) differentiation ratio
(percent of all nuclei fused into fibers). Scale bar is 100mm. Color images available online at www.liebertpub.com/tec
FIG. 5. Tracking of transplanted
hMPCs by MRI. Unlabeled (con-
trol) and 400mg/mL labeled
hMPCs were subcutaneously in-
jected in the back of nude mice
before scanning by MRI 4 days, 1
week, 2 weeks, and 4 weeks after
injection. The area of interest in
representative T2-weighted MRI
images is shown and injected cells
are marked with an arrow. Two
representative mice are shown for
injections with both control cells
and SPIO-labeled hMPCs.
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great promise,20 but its safety and efficacy has to be evaluated
for each cell type and SPIO independently.
While cells are generally capable of absorbing iron ox-
ide nanoparticles by endocytosis, nonphagocytic or slow
dividing cells usually require the use of a transfection re-
agent to enhance the uptake,30,31,34,37 which by itself can
have adverse effects on cells.38 Furthermore, the use of such
agents may complicate translation into clinics, as substances
like poly-L-lysine lack FDA-approval. In this study, hMPCs
incorporated the SPIO nanoparticles in a concentration-
dependent manner, showing a homogeneous distribution of
the particles even without the addition of a transfection re-
agent (Fig. 1). This is in good agreement with an early work,
which demonstrated that porcine skeletal muscle-derived cells
were efficiently labeled with SPIOs alone.39 Similarly, human
MSCs (hMSCs) could also be labeled with SPIOs alone,
however, the efficiency was lower when compared with novel
citrate-coated SPIOs.40 As the internalization step is nonspe-
cific and happens via endocytosis, the absorption rate is influ-
enced not only by the size41,42 but also by the coating40,43–45 of
the SPIOs. Nanoparticle uptake appears to be furthermore
dependent on the exact cell type, as in a murine model, muscle-
derived stem cells displayed a poor labeling efficiency with
SPIOs alone and necessitated the application of a transfection
agent.46 Interestingly, showing almost complete loss of SPIOs
by MSCs between 7 and 22 days in vitro, not only SPIO uptake,
but also intracellular retention of the nanoparticles was dem-
onstrated to be cell- and nanoparticle-type dependent.47 In
good agreement, culture expansion of hMPCS for one passage
(*7 days) similarly displayed a strong reduction in intracel-
lular iron staining (Fig. 1), suggesting that the loss of SPIOs
occurs due to the rapid proliferation of the cells in vitro.
Coated SPIO nanoparticles are generally considered to be
relatively nontoxic48 and while a high SPIO uptake efficiency
FIG. 6. Histological analysis of the newly formed muscle tissues. After myogenic in vivo differentiation, tissues formed by
unlabeled (control) and 400mg/mL labeled hMPCs were harvested and evaluated by (a) H&E staining and immunostaining for
muscle markers desmin, myosin heavy chain (MyHC), anda-actinin 4 weeks after MPC injection; scale bar is 50mm and (b)Prussian
blue staining for iron after 1, 2, and 4 weeks after injection, with a higher magnification shown in (c)Scale bar is 50mm. (d)Uptake of
SPIO nanoparticles by macrophages was evaluated 4 weeks after injection via co-staining with Prussian blue and marker F4/80 for
mouse macrophages. Scale bar is 100mm. H&E, hematoxylin and eosin. Color images available online at www.liebertpub.com/tec
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is desirable from an imaging standpoint, high nanoparticle
loads can have negative effects on cell viability and differ-
entiation.23–25,27–30,40 Data regarding possible negative effects
of SPIO labeling are, however, difficult to compare, and while
the majority of studies did not show detrimental effects on
various cell types,20 an inhibitory effect of SPIO labeling on
chondrogenic but not adipogenic or osteogenic differentiation
of hMSCs at a concentration of 500mg/mL has been shown
recently.40 Being in good agreement with the majority of
studies, the results in this work displayed no negative effect on
cell viability at concentrations up to 200mg/mL with only a
minor decrease at 400mg/mL. At concentrations of 800 and
1600mg/mL however, viability decreased significantly (Fig.
3a). Interestingly, there were no changes in the proliferation
rate (Fig. 3b, c), expression of skeletal markers, or differen-
tiation capacity (Fig. 4) of hMPCs irrespective of the SPIO
concentration, suggesting that myogenic differentiation is a
more robust process compared with chondrogenic differenti-
ation of hMSCs.
Regarding the optimal SPIO concentration for MRI cell
tracking, previous work has shown a correlation between the
applied nanoparticle concentration and loss of MRI sig-
nal intensity.40 This is in good agreement with the results
observed in this study, showing a concentration-dependent
MRI signal loss, which was very high directly after labeling
of hMPCs, and while much weaker, still well detectable
after one passage of proliferation, which corresponds to 9
population doublings (Fig. 2). About 400 mg/mL was found
to be best compromise between a high nanoparticle load, a
high signal alteration in MR images, and a minimal negative
effect on cell viability and was thus implemented for all
subsequent experiments. When injecting the SPIO-labeled
hMPCs into the subcutaneous space of nude mice, the cells
were visible as a hypointense entity in the MR images
over a period of 4 weeks (Fig. 5). Similar time frames have
been reported previously when tracking SPIO-labeled cells
in vivo.46,49 The observed discrepancy between the rapid
loss of labeling in vitro and the extended signal retention
in vivo can possibly be explained twofold. On the one hand,
the cells in vitro were kept in a proliferative state under-
going several rounds of cell division, whereas in vivo, the
cells only fused once to form mature muscle fibers. On the
other hand, SPIOs lost by the cells in vitro were removed
upon changing the medium but were taken up by macro-
phages in the vicinity of the hMPCs in vivo (Fig. 6), thereby
continuing to contribute to the negative MRI-signal, which
is a problem inherent to SPIO labeling cells. Noteworthy,
unlabeled MPCs were also visible in the MRI as a well-
defined hyperintense area for at least 2 weeks, potentially
reflecting fluid from the injection, a local inflammatory re-
action or a combination of the two, but injections were
hardly detectable thereafter. Based on the MR images with
labeled hMPCs and measurements of sample weights after 2
and 4 weeks in vivo, the injection volume greatly decreased
over the course of 4 weeks, which likely occurs due to the
fusion of cells into myofibers and the concomitant re-
modeling of the collagen carrier. While the subcutaneous
injections of labeled cells can be detected in T2-weighted
images over the course of up to 4 weeks despite this shrink-
age, localizing unlabeled cells may not be possible when
applied as an intramuscular injection.
In stem cell therapy approaches, the fate of the injected
cells in vivo is a major concern and even though autologous
adult stem or progenitor cells are generally considered to be
safe, the in vitro expansion and manipulation procedures may
adversely affect the therapeutic quality of the cells.12 While
whole myofiber implants have been suggested as a superior
alternative to culture expanded muscle progenitor cells,50
immunohistofluorescence stainings demonstrated that both the
labeled and unlabeled cells formed muscle fibers, which
strongly expressed specific markers of skeletal muscles (Fig.
6). Moreover, functionality of the newly formed muscle tissue
could be demonstrated by myography (Fig. 7), confirming that
hMPCs isolated from patient biopsies retain their capacity to
form contractile muscle tissue after in vitro culture expansion
and SPIO labeling. Using the identical protocol for hMPC
isolation and in vitro culture expansion, it was previously
demonstrated that such cells were able to restore a damaged
sphincter muscle in dogs for up to 6 months.14 Similar results
were also obtained in rats using allogenic MPCs.51
A further aspect when injecting labeled cells in vivo is the
localization of SPIO in the engineered tissue. SPIO nano-
particles cleared from the cells over time through exocytosis,
when cells undergo cell division or upon cell death can be
taken up by the monocyte/macrophage system52,53 and the
potential transfer/uptake of SPIO nanoparticles by macro-
phages from labeled hMSCs has been shown previously.54 In
this study, tissue sections of bioengineered muscle tissue re-
vealed that nanoparticles remained inside the newly formed
muscle fibers but could also be detected localized to tissue
macrophages (Fig. 6). While this suggests that nanoparticles
were cleared to some extent from the hMPCs during the fusion
process of myofiber formation, the injected hMPCs were not
engulfed by macrophages but instead formed functional mus-
cle tissue. Importantly, the sensitivity of the MRI can be ad-
justed by altering the sequence parameters (i.e., shorter/longer
echo time TE), and the amount of SPIO nanoparticles incor-
porated in muscle fibers could thus still enable long-term cell
tracking upon macrophage clearance from the site of injection.
Unfortunately, Endorem has been taken from the market
for commercial reasons and also Resovist is no longer com-
mercially available. However, with cell therapy being a re-
search area of great interest and potential, it is likely only a
matter of time before more contrast agents will be available or
FIG. 7. Assessment of tissue contractility via myography.
After 4 weeks of myogenic in vivo differentiation, tissues
formed by unlabeled (control) and 400mg/mL labeled hMPCs
were harvested and contractility was assessed in response to
40 V/40 Hz and 80 V/80 Hz electrical stimulation. Contractions
of three muscle tissues normalized to their weight (mg/mg)
were used for comparison.
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before production of discontinued agents such as Endorem
will be resumed. For example, Ferumoxytol (Feraheme), an
ultrasmall SPIO that has recently been approved by the FDA
for iron supplementation therapy, efficiently labels hMSCs
when used off-label.55
Conclusion
The herein presented data clearly demonstrate that pri-
mary hMPCs can be labeled with an FDA approved SPIO
without the use of an additional transfection agent and that
the labeled cells retain the expression of characteristic markers
of skeletal muscles and form functional tissue engineered skel-
etal muscle in vivo. Furthermore, the location of the stem cell
injection can be visualized by MRI in vivo up to 1 month. Such a
monitoring strategy is essential to ensure safety and efficacy of
future cell therapies for muscle regeneration in patients affected
by SUI and other applications in regenerative medicine.
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